ArticleFrontiers in health services2026
Trust and trade: patient perspectives on the ethics of real-world data monetisation.
Article in Frontiers in health services, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Real-world data (RWD) and real-world evidence (RWE) are increasingly used to inform regulatory decisions, health technology assessment, and health system planning. However, patients whose data underpin these activities often experience limited transparency or benefit when their information is monetised. While regulatory and HTA frameworks emphasise methodological rigor and analytical transparency, they provide limited guidance on fairness, reciprocity, and legitimacy from a patient perspective. This Policy Brief examines this governance gap and argues that evidence integrity must extend beyond technical standards to include ethical stewardship and public trust. Drawing on policy contexts from UK, EU, and North America, it proposes five pragmatic safeguards to strengthen transparency, accountability, and patient-centred governance in secondary data use, supporting the sustainability and legitimacy of RWE infrastructures as data initiatives expand.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.